PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Gencurix is expanding exports of its breast cancer prognostic test GenesWell BCT into Europe and China, with revenue rising and operating losses narrowing, while recurring external financing needs and liquidity concerns persist alongside this growth.
Q2 2026 revenue reached KRW 2.989 billion, the highest quarterly figure in the recent window, while the operating loss narrowed to KRW 701 million, the smallest in the past five quarters.
Starting in May 2026, the company began European exports of four CE-IVDR-certified cancer diagnostic kits through Bio-Rad.
In June 2026, Gencurix signed a partnership with Guorun International Medical Group to supply GenesWell BCT in southern China.
The absorption merger of Genopeaks (effective September 1, 2026) brought in liquid biopsy assay know-how and a medical expert network, with merger-related new shares scheduled to list on September 23.
Liquidity issues tied to short-term borrowings, convertible bonds, and redeemable convertible preferred shares have repeatedly surfaced, and the company has officially denied rumors of a management rights sale.
Gencurix is a KOSDAQ-listed molecular diagnostics company developing and commercializing cancer diagnostic solutions, with GenesWell BCT as its core product, a prognostic test predicting the need for chemotherapy after breast cancer surgery.
GenesWell BCT is a gene-based test that evaluates recurrence risk and treatment benefit to support personalized treatment strategies.
The company also offers a digital PCR-based companion diagnostic kit lineup called Droplex, covering lung, colorectal, thyroid, and endometrial cancers, along with liquid biopsy-based diagnostic solutions.
Rather than building its own overseas sales force, Gencurix relies on partnerships with global diagnostics companies; it has a supply agreement with Bio-Rad Laboratories covering Droplex across 32 European countries, and it continues to expand collaboration with Roche Diagnostics and Qiagen.
In the China market, Gencurix partnered with healthcare services firm Guorun International Medical Group to supply GenesWell BCT across southern Chinese regions including Hainan and Guangdong.
Through the absorption merger of Genopeaks, effective September 1, 2026, the company acquired liquid biopsy assay development know-how and a medical expert network built around faculty from leading domestic medical schools.
In terms of competitive landscape, comparable domestic molecular diagnostics companies include NGeneBio, Aptamer Sciences, GenBody, and NanoBioLife, while globally, large diagnostics companies serve as both distribution partners and potential competitors.
The company also addressed governance matters at an extraordinary shareholders' meeting on September 9, 2026, where a director appointment agenda was handled.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩2B | -₩1.3B | −65.5% |
| 2025Q3 | ₩1.7B | -₩1.6B | −94.4% |
| 2025Q4 | ₩2.1B | -₩2.1B | −97.3% |
| 2026Q1 | ₩2.1B | -₩1B | −48.0% |
| 2026Q2 | ₩3B | -₩700M | −23.5% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩2.6B | -₩11B | -₩24.6B | −430.1% | −379.9% | 556.4% |
| 2023 | ₩2.6B | -₩11.2B | -₩19.3B | −429.1% | −139.8% | 179.1% |
| 2024 | ₩5.1B | -₩8.5B | -₩4.1B | −166.1% | −27.8% | 101.7% |
| 2025 | ₩7.5B | -₩6.6B | -₩7.4B | −87.0% | −45.1% | 96.1% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Annual revenue rose for four consecutive years, from KRW 2.559 billion in 2022 to KRW 2.600 billion in 2023, KRW 5.134 billion in 2024, and KRW 7.548 billion in 2025.
Operating losses, by contrast, widened from KRW 11.007 billion in 2022 to KRW 11.159 billion in 2023 before narrowing to KRW 8.529 billion in 2024 and KRW 6.568 billion in 2025.
Net loss attributable to owners followed a similar pattern, falling sharply from a large KRW 24.597 billion loss in 2022 and KRW 19.260 billion in 2023 to KRW 4.148 billion in 2024, before widening again to KRW 7.386 billion in 2025.
On a quarterly basis, the operating loss actually widened from KRW 1.632 billion in Q3 2025 (on revenue of KRW 1.728 billion) to KRW 2.055 billion in Q4 2025 (on revenue of KRW 2.112 billion), but the most recent two quarters showed simultaneous revenue growth and loss narrowing, with Q1 2026 posting revenue of KRW 2.101 billion and an operating loss of KRW 1.009 billion, followed by Q2 2026 revenue of KRW 2.989 billion and an operating loss of KRW 701 million.
Net loss attributable to owners, however, widened to KRW 2.371 billion in Q1 2026 before narrowing to KRW 1.285 billion in Q2 2026, reflecting greater volatility in non-operating items than in operating results.
Operating cash flow remained negative by roughly KRW 10 billion annually from 2022 through 2025 (KRW -6.241 billion in 2025), underscoring a continued reliance on external financing rather than internal cash generation.
On the balance sheet side, the debt ratio improved markedly, falling from 556.4% in 2022 to 179.1% in 2023, 101.7% in 2024, and 96.1% in 2025, reflecting the impact of capital-raising efforts such as rights offerings and asset sales.
That said, consolidated non-controlling interests were in deficit in both 2022 (KRW -802 million) and 2023 (KRW -1.773 billion), indicating that losses at subsidiary operations had been substantial.
The global molecular diagnostics and companion diagnostics market is generally considered a structurally growing segment, driven by the expansion of precision medicine and the personalization of cancer treatment.
The breast cancer prognostic testing field had already been established in Western markets, whereas Asia had relatively few products reflecting ethnic genetic differences, a gap that GenesWell BCT was designed to address.
Liquid biopsy and digital PCR technologies are seeing expanded use in cancer diagnostics due to their less invasive nature and suitability for repeat testing compared with tissue biopsy.
Gencurix relies on the distribution networks of large global diagnostics companies such as Bio-Rad, Roche Diagnostics, and Qiagen rather than building its own sales force, an approach that lowers the risk of overseas market entry but increases dependence on partners for margin and negotiating leverage.
In China, the company is lowering entry barriers by partnering with local healthcare network operators such as Guorun, with the Hainan Boao Lecheng International Medical Tourism Pilot Zone serving as a hub supporting early introduction of innovative foreign medical devices.
In the domestic molecular diagnostics field, a number of similarly sized technology-based companies such as NGeneBio, Aptamer Sciences, GenBody, and NanoBioLife compete in a relatively fragmented market, with many individual companies still at an early growth stage where revenue scale remains modest.
Starting in May 2026, Gencurix began initial supply of four CE-IVDR-certified cancer diagnostic kits (KRAS, cMET, BRAF, POLE) to Europe through Bio-Rad, which the company describes as the start of actual order-based revenue generation.
In June of the same year, it signed a partnership with Guorun International Medical Group to supply GenesWell BCT across southern China, with plans to pursue local introduction starting in Hainan and Guangdong.
On the diversification front, the company was selected as a joint research institution for a roughly KRW 29.4 billion cross-ministerial advanced medical device R&D program, under which it will develop a next-generation digital PCR platform through 2032, and it was also selected for a Ministry of Health and Welfare low-birthrate-related technology development project being conducted with researchers at Gangnam CHA Hospital.
The absorption merger with Genopeaks was completed effective September 1, 2026, with 742,456 merger-related new shares scheduled to list on September 23; the company stated it plans to use the acquired liquid biopsy assay know-how and medical expert network to strengthen the clinical utility of GenesWell BCT, expand adoption of its lung and colorectal cancer companion diagnostic products, and discover new biomarkers.
On the liquidity side, regarding short-term borrowings maturing in August, the company stated in a July 2026 position paper that most of the debt is real-estate-backed financing that is renewed annually and that the relevant extensions had already been completed.
How much of the European and Chinese export activity translates into actual revenue, and whether operating cash flow can improve without repeated external financing, are likely to remain key variables for future results.
With operating and net losses persisting, the price-earnings ratio remains difficult to compute, a condition tied to a multi-year loss pattern.
The price-to-book ratio tends to trade at a level that reflects some premium over net asset value, and since the company does not pay dividends, a dividend-yield-based comparison is not applicable.
Revenue has shown a clear multi-year upward trend and the operating loss has directionally narrowed, but net income has fluctuated due to non-operating factors, making it premature to characterize this as a full-fledged earnings recovery.
Repeated changes to the capital structure—including rights offerings, convertible bonds, and merger-related new share issuances—warrant caution when interpreting per-share metrics.
Valuation is likely to hinge on how quickly European and Chinese export activity translates into actual revenue and whether the company can restore its own cash-generating capacity.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
Q2 2026 revenue reached KRW 2.989 billion, the highest in the past five quarters, while the operating loss shrank to KRW 701 million, the smallest over the same period. Annually, revenue has risen for four consecutive years since 2022, confirming a pattern of business expansion.
Net income, however, has fluctuated due to non-operating factors, so the durability of this trend requires further confirmation.
The supply agreement covering 32 European countries through Bio-Rad, and the start of initial shipments of four CE-IVDR-certified kits in May 2026, could mark the beginning of substantive overseas revenue generation.
In China as well, the partnership with Guorun is advancing entry into Hainan and Guangdong, indicating ongoing regional diversification. Relying on the distribution networks of large global partners reduces the burden of building an in-house sales organization.
The absorption merger with Genopeaks, effective September 1, 2026, brought in liquid biopsy assay development know-how and a medical expert network built around faculty from leading domestic medical schools.
The company stated it plans to use these assets to strengthen the clinical utility of GenesWell BCT and discover new biomarkers. Merger-related new shares are scheduled to list on September 23, providing a potential foundation for portfolio expansion.
From 2022 through 2025, operating losses exceeded KRW 6 billion annually alongside negative operating cash flow.
In 2025, operating cash flow was KRW -6.241 billion, indicating a continued structure in which the business cannot be run on internally generated cash alone, which can lead to repeated dependence on external financing.
In July 2026, some media outlets highlighted liquidity risk by comparing cash and cash equivalents at the end of Q1 with short-term borrowings maturing in August, which also gave rise to rumors of a management rights sale.
The company officially denied the sale rumors and explained that most of the borrowings are real-estate-backed loans renewed annually, but the fact that cash and cash equivalents remain limited is difficult to dispute.
The company has raised funds or altered its capital structure through various means, including convertible bonds, third-party allocated rights offerings, subsidiary equity stake sales, and the issuance of merger-related new shares for Genopeaks.
Regarding subsidiary Genobio, an exercise of a put option by redeemable convertible preferred share investors has been reported, which has been cited as an additional source of cash outflow. Such recurring capital-raising activity can be linked to potential dilution of existing shareholders.
The debt ratio improved substantially from 556.4% in 2022 to 96.1% in 2025, but liabilities still stand close to the level of equity, and the structural inability to generate cash from operations persists.
Repeated maturity extensions on short-term borrowings, along with redemption demands related to convertible bonds and redeemable convertible preferred shares, could recur, potentially necessitating further rights offerings or asset sales.
Consolidated non-controlling interests were in deficit in both 2022 and 2023, indicating that certain subsidiaries carried substantial losses.
Reported cases involving the exercise of subsidiary-related RCPS put options and the recognition of allowances against loan receivables suggest that weak subsidiary performance could impose additional burdens on the parent company's cash flow.
European export activity depends on maintaining CE-IVDR certification and on continued ordering by global partners, and it remains to be further confirmed whether initial shipments will lead to sustained reorders.
Entry into the China market likewise depends on the Guorun partnership and must proceed through local regulatory and approval procedures in zones such as Hainan, which could result in delays beyond current expectations.
This is the scheduled listing date for the 742,456 new shares issued in the Genopeaks absorption merger; the resulting dilution and the effect of incorporating liquid biopsy assets warrant confirmation.
This is the point to check how much European and Chinese export revenue is reflected in Q3 results and whether the operating loss narrowing trend continues for more than two consecutive quarters.
Whether Bio-Rad places reorders for Europe, and the progress of local introduction of GenesWell BCT in southern China through the Guorun partnership, should be confirmed through further disclosures or news reports.
Even after the company's stated completion of repayment extensions, it is necessary to continue monitoring for further maturity extensions or new disclosures of rights offerings or asset sales.
Gencurix is expanding European and Chinese export partnerships centered on GenesWell BCT, and its Q2 2026 results showed early signs of business expansion, with simultaneous revenue growth and operating loss narrowing.
At the same time, the absorption merger with Genopeaks has broadened its R&D base by adding liquid biopsy technology and a medical expert network.
However, negative operating cash flow persisting since 2022, recurring reliance on external financing, and liquidity-related controversy that surfaced during 2026 leave financial stability challenges apart from the growth narrative.
While the marked improvement in the debt ratio is a positive, liabilities remain close to equity levels, and potential risks such as subsidiary-related losses and RCPS put options also exist.
How much European and Chinese export activity translates into actual revenue, and whether the company can restore its own cash-generating capacity, are likely to be the key variables shaping its trajectory going forward. Investment judgment should weigh these growth factors and financial risks together in a balanced manner.
Report written 2026-09-12 · Data as of 2026-09-11
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.